NRG Oncology/GOG Studies
- The purpose of this study was to assess the prognostic significance of a simplified, clinically accessible classification system for endometrioid endometrial cancers combining Lynch syndrome screening and molecular risk stratification.
- Endometrial carcinoma is the fourth most common malignancy among women world-wide and is the most common gynecologic cancer . Endometrial cancer is broadly categorized into three histologic types: endometrioid adenocarcinoma (EEA), accounting for up to 75% of cases, serous adenocarcinoma (ESA), accounting for an additional 20% of cases and carcinosarcoma (UCS), which makes up most of the remaining cases . In general, EEA has a better prognosis and a low recurrence risk, while ESA and UCS are more aggressive with accordingly worse prognosis and increased recurrence risk.
- To report clinical and pathologic relationships with disease spread in endometrial cancer patients.
- GOG 152 was a randomized trial of secondary cytoreductive surgery (SCS) in patients with suboptimal residual disease (residual tumor nodule >1 cm in greatest diameter) following primary cytoreductive surgery for advanced stage ovarian cancer. The current analysis was undertaken to evaluate the impact of disease findings at SCS on progression-free survival (PFS) and overall survival (OS).
- Few studies have analyzed relationships between risk factors for endometrial cancer, especially with regard to aggressive (non-endometrioid) histologic subtypes, and prognosis. We examined these relationships in the prospective NRG Oncology/Gynecologic Oncology Group 210 trial.